TABLE 3.
Pharmacokinetics of rosuvastatin in individuals with different SLCO1B1 genotype‐predicted OATP1B1 functions
| Variable | Highly increased (n = 4) | Increased (n = 44) | Normal (n = 124) | Decreased (n = 63) | Poor (n = 12) | ||||
|---|---|---|---|---|---|---|---|---|---|
| Mean (90% CI) | Ratio to normal (90% CI) P‐value | Mean (90% CI) | Ratio to normal (90% CI) P‐value | Mean (90% CI) | Mean (90% CI) | Ratio to normal (90% CI) P‐value | Mean (90% CI) | Ratio to normal (90% CI) P‐value | |
| C max (ng/mL) | 10.4 (6.8–15.9) | 0.64 (0.40–1.02) P = .12 | 14.8 (11.8–18.4) | 0.91 (0.68–1.22) P = .59 | 16.2 (13.4–19.7) | 19.6 (17.1–22.6) | 1.21 (0.95–1.54) P = .19 | 45.0 (33.9–59.9) | 2.77 (1.97–3.91) P = 1.75 × 10−6 |
| AUC0‐∞ (ng × h/mL) | 83.8 (58.2–120.7) | 0.56 (0.38–0.84) P = .019 | 140.9 (116.7–170.1) | 0.95 (0.73–1.22) P = .71 | 149.0 (126.3–176.0) | 180.5 (160.0–203.8) | 1.21 (0.99–1.49) P = .13 | 312.0 (244.4–398.6) | 2.09 (1.56–2.81) P = 4.69 × 10−5 |
| t ½ (h) | 12.1 (8.9–16.5) | 1.11 (0.79–1.56) P = .62 | 11.7 (10.0–13.8) | 1.07 (0.87–1.32) P = .60 | 11.0 (9.5–12.6) | 11.1 (10.0–12.3) | 1.00 (0.85–1.20) P = .93 | 11.2 (9.1–13.7) | 1.02 (0.79–1.30) P = .91 |
Data are estimated marginal means adjusted for weight (AUC0‐∞ and C max), SLCO2B1 c.1457C > T genotype and ABCG2 c.421C/A genotype. AUC0–∞, area under the plasma concentration–time curve from zero to infinity; CI, confidence interval; C max, peak plasma concentration; t ½, elimination half‐life.